Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from August 15, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 13, 2025 — +11.6% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted
$82.60 Published $90.83 Target $92.14 Window close $93.46 Peak
$80.01 – $81.94Entry zone — fair-value band
$82.60Published — price the day we called it
$90.83Target — the price the thesis aimed for
$93.46Peak — highest point inside the window, not a realized return
$92.14Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 90 days.

At window close
+11.6%
realized, from the publication price to the last close inside the window
Peak gain
+13.1%
peak, from the publication price — not a realized return
S&P 500, same window
+4.7%
SPY over the identical days, dividend-adjusted
Window close
$92.14
last close inside the window, ended November 13, 2025
Peak price
$93.46
peak on November 13, 2025 — not a realized return
Days to target
90

The thesis — published August 15, 2025

Predicted growth
+12%
over the measurement window
Target price
$90.83
the price the thesis aimed for
Entry zone
$80.01 – $81.94
the fair-value band we waited for
Price at publication
$82.60
published August 15, 2025
Confidence
68%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Merck shows steady buying interest, with the recent average price trending up and more buyers than usual. A popular value checklist gave it a strong 93% score this week, even though second-quarter revenue fell short, so views are ahead of results. In a somewhat positive market, big drug makers can edge higher. Over the next 1-3 months we expect modest gains, with policy news and cancer rivals as key risks.

Primary drivers

  • Recent average price is rising, and more buyers than usual are active
  • Strong investor enthusiasm that puts the stock among leaders
  • A well-known value checklist gives the stock a strong 93% score
  • Second-quarter sales came in light, which cools the otherwise strong story

How it played out

MRK: target reached in 90 days

Lyra published MRK on 2025-08-15 at $82.60. The thesis expected 12% growth and pointed to a rising recent average price, more buyers than usual, strong investor enthusiasm, and a value checklist score of 93%. It also noted that second-quarter sales had come in light, which cooled the otherwise strong setup.

Inside the window, MRK rose above the $90.83 target. The peak was $93.46 on 2025-11-13, with a peak gain of 13.1%. The target was reached in 90 days. The stock ended at $92.14. The thesis played out.

What happened during the window

On Oct. 30, 2025, Investor's Business Daily reported that Merck topped third-quarter forecasts, raised its 2025 profit guidance, and narrowed its sales outlook.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals